AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04029103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knowledge, behaviour, self efficacy
Description: Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
Study NCT04029103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knowledge, behaviour, self efficacy
Description: Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
Study NCT03006692 — intervention group
Intervention type: OTHER
Intervention: With arterial blood gas, parameters not being normal can be corrected
Description: If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
Study NCT02349750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial scratch injury
Description: ESI using No.8 neonatal feeding tube
Study NCT00877396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
Study NCT00877396 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
Study NCT04095091 — intervention group
Intervention type: DEVICE
Intervention: 4D Planar US Transducer
Description: This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
Study NCT01799551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ca CBT
Description: Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
Study NCT00788710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663) 120 mg
Description: 120 mg of etoricoxib (MK0663) for a total of 5 days
Study NCT02631863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with illumination
Study NCT04260737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid for Men with Localized Prostate Cancer
Description: The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
Study NCT00788710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Study NCT00788710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib (MK0663) 90 mg
Description: 90 mg of etoricoxib (MK0663) for a total of 5 days
Study NCT04238169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg once every three weeks
Study NCT04238169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg once every three weeks
Study NCT04238169 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 30-50Gy/5F（2-4 lesions）
Study NCT03404297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Locally sourced compression therapy
Description: The dressing is made up of a zinc oxide impregnated compression wrapping
Study NCT03404297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locally sourced compression therapy
Description: The dressing is made up of a zinc oxide impregnated compression wrapping
Study NCT02343198 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Custom-built research muscle stimulator
Description: Muscle stimulator
Study NCT02343198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-built research muscle stimulator
Description: Muscle stimulator
Study NCT00005834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
Study NCT00005834 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Arms 1 and 2: 300 mcg (pts \</= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Arms 1 and 2: 40 mg/d PO days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Arms 1 and 2: 40 mg/d PO days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
Study NCT00005834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Arm 2: 800 mg/d (max dose) PO daily
Study NCT01990859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01399320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate
Description: excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
Study NCT02709876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Patch
Description: MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0873 Cream
Description: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
Study NCT02952027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use-recording, patient-reminder alarm for incentive spirometry
Study NCT00056472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: 10-20mg/day
Study NCT00056472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10-20mg/day
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plain patch
Description: Plain patch containing no MK-0873 or placebo
Study NCT01140061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plain patch
Description: Plain patch containing no MK-0873 or placebo
Study NCT04313478 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low Birth Weight and Normal Weight infants
Description: This cross-sectional study included LBW and NW infants at between 3 and 9 months of age. The levels of trunk control were investigated by using the Segmental Assessment Trunk Control (SATCo). The Alberta Infant Motor Scale (AIMS) were used for assessment of gross motor performance and identify typical and atypical motor development of infants.
Study NCT04374955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Activia Probiotics Shot
Description: The product contains Actiregularis - at least 2x106 cfu / g.
Study NCT04374955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine care of the hospital will be provided.
Study NCT04374955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care of the hospital will be provided.
Study NCT04957056 — intervention group
Intervention type: PROCEDURE
Intervention: Hospitalization
Description: Hospitalization
Study NCT00459654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
Study NCT00459654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
Study NCT01078844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: memantine 5-20 mg daily
Study NCT01078844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look-alike placebo
Study NCT00562562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: osteopathic manipulative treatment
Description: Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805
Description: Active Investigational Drug
Study NCT00056472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 150-200mg/day
Study NCT00056472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet that ressembles sertraline but contains no medication
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Standard of Care drug
Study NCT04294511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Description: camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
Study NCT03535428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VENOUS exploration
Description: venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
Study NCT01854905 — intervention group
Intervention type: OTHER
Intervention: No Treatment
Description: Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
Study NCT00316758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses bid
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Standard of Care drug
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Standard of Care drug
Study NCT03911440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Study NCT03911440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Description: Standard chemotherapy
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
Description: Standard chemotherapy
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Standard chemotherapy
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Standard of Care drug
Study NCT00316758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, in patients who were in study BM18249
Study NCT00425204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (ABX-EGF)
Description: Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2336805 Matching Placebo
Description: Placebo of Investigational Drug
Study NCT01439373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2336805 Matching Placebo
Description: Placebo of Investigational Drug
Study NCT00830180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NGF AB
Description: Solution for injection, 10 mg, one injection/8 weeks
Study NCT02868047 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Description: Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
Study NCT04305561 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast-enhanced ultrasound
Description: Ultrasound contrast agent: Stabilized sulfur hexafluoride microbubbles (SonoVue®, Bracco).~An 18 G needle will be placed in an antecubital vein and directly attached to a three-way stopcock with an extension tube.~The SonoVue® will be prepared and shaken shortly before injection in accordance with the instructions provided in the product information leaflet.~The patient will be injected with 1.2 ml SonoVue® at a pace of 1-2 ml/s using the 180 degree straight-flow channel of the three-way stopcock, directly followed by a 10 ml bolus of sodium chloride 9 mg/mL (0.9%) injected into the 90 degree channel of the three-way stopcock at a pace of approximately 2 ml/s.~A full examination will typically require one to two injections of 1.2 ml of SonoVue® (one injection per suspected parathyroid adenoma).
Study NCT01796821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study NCT01796821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 1.0 % SM
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study NCT01796821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 2.3% SM
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study NCT05417191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fish
Description: Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Study NCT05417191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched fish
Description: Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Study NCT01431391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study NCT01431391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 45.0 mg depot injection, 2 doses 6 months apart
Study NCT03931694 — intervention group
Intervention type: DEVICE
Intervention: e-DOL
Description: e-health program (smartphone and web platform)
Study NCT04367090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, trastuzumab
Description: Docetaxel and trastuzumab once per cycle
Study NCT03204448 — intervention group
Intervention type: DEVICE
Intervention: BioCLIA Ro60
Description: BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
Study NCT04367090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400/320 mg orally daily
Study NCT04083157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine with imiquimod
Description: Intradermal hepatitis B vaccine with topical imiquimod pretreatment
Study NCT04083157 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular hepatitis B vaccine with aqueous cream
Description: Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
Study NCT00963066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSV - pressure suppot ventilation
Description: Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
Study NCT00963066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA - Neurally Adjusted Ventilatory Assist
Description: Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
Study NCT00963066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA - EMG
Description: Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
Study NCT01061801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional expression
Description: Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
Study NCT01061801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional expression
Description: Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
Study NCT03348618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Intravenous immunoglobulin
Study NCT02368418 — intervention group
Intervention type: PROCEDURE
Intervention: PCP
Description: PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
Study NCT02368418 — intervention group
Intervention type: PROCEDURE
Intervention: SRS
Description: SRS is short for a community-based Salt Reduction program delivered by community health educators.
Study NCT00739063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.